Novo Nordisk to build new corporate centre in Bagsværd, Denmark

Novo NordiskNovo Nordisk is investing around 1 billion Danish kroner (134 million euros) in two new office buildings with surrounding green space in Bagsværd, Denmark. The project is expected to create more than 300 jobs during the construction phase. The new office premises will house Novo Nordisk's top management, 1,100 administrative employees and a number of shared facilities. Groundbreaking will take place in October, and the new corporate centre is expected to be ready for occupancy at the end of 2013.

With the new premises, Novo Nordisk will be consolidating a number of administrative functions currently scattered across Greater Copenhagen. In future, the employees will be gathered at new, contemporary offices at the Bagsværd and Søborg sites.

"Although Novo Nordisk is primarily set to grow outside of Denmark in the coming years, we are looking forward to consolidating the administrative functions in Bagsværd, where we have been present since the 1950s. The new buildings will give our employees the best conditions for interacting across functional divides and with our colleagues abroad," says Lars Rebien Sørensen, president and CEO of Novo Nordisk.

The insulin molecule with its contoured spiral shape was a key source of inspiration for Henning Larsen Architects. The new building will be distinctive in its white materials combined with Nordic stone and woods. The aim is to create a dynamic and inspiring work setting closely allied with external natural features, in an elegant, streamlined and efficient centre for Novo Nordisk.

Around 14,000 of Novo Nordisk's 32,000 employees work in Denmark. Beyond the Copenhagen area, Novo Nordisk has activities in Kalundborg, Hillerød, Værløse, Måløv and Hjørring.

About the building project

  • The new corporate centre will consist of two office buildings - a circular, six-storey building and a lower, four-storey building, underground parking and a large planted landscape.
  • Situated on a 37,000 m2 site, the new buildings will take up an area of 8,800 m2 with a total floorage of 50,500 m2.
  • The buildings will feature low energy consumption with the aid of sensors, light and ventilation, and will meet the 2015 energy requirements for new buildings.

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...